S&P upgrades Teva to BBB- as MFN talks and notes plan progress
Teva Pharmaceutical Industries Ltd (TEVA) gained investment-grade status after S&P upgraded it to BBB-. Teva also joined nine drugmakers in MFN talks tied to at least $19.6B in U.S. manufacturing investment and plans EUR/USD unsecured notes.